Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAMAVAQ NeoVaccine + Poly-ICLC + cGAMP + granulocyte-macrophage colony stimulating factor + imiquimod + CpG oligodeoxynucleotides + saponins + monophosphoryl lipid A
- Development stage
- Unknown
- Lead developer
- Biogenea
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intradermal, Subcutaneous, Topical (imiquimod), Possibly Others Depending On Component
01
Overview
This investigational combination immunotherapy comprises TAMAVAQ NeoVaccine, a personalized cancer vaccine, co-administered with several innate immune system adjuvants and stimulators, including Poly-ICLC (a synthetic double-stranded RNA agonist), cGAMP (a STING agonist), granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod (a TLR7 agonist), CpG oligodeoxynucleotides (TLR9 agonists), saponins (plant-derived adjuvants), and monophosphoryl lipid A (TLR4 agonist). The aim is to elicit a robust anti-tumor immune response. The combination is under investigation primarily for glioblastoma, with a focus on safety and immunogenicity[1][2].
02
Targets
Cell membrane cholesterol-rich microdomainCSF2R (Granulocyte-macrophage colony-stimulating factor receptor)STING (Stimulator of interferon genes protein)γδ TCR (T-cell receptor)TLR3 (Toll-like receptor 3)TLR4 (Toll-like receptor 4)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on TAMAVAQ NeoVaccine + Poly-ICLC + cGAMP + granulocyte-macrophage colony stimulating factor + imiquimod + CpG oligodeoxynucleotides + saponins + monophosphoryl lipid A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAMAVAQ NeoVaccine + Poly-ICLC + cGAMP + granulocyte-macrophage colony stimulating factor + imiquimod + CpG oligodeoxynucleotides + saponins + monophosphoryl lipid A.